The article you requested is
Effects of Bupropion Augmentation in Escitalopram-Resistant Patients With Major Depressive Disorder: An Open-Label, Naturalistic Study
J Clin Psychiatry 2009;70(7):1054-1056 [letter]
Copyright 2009 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
- Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: There is a pressing need for improvement of treatment response
to antidepressants in depression. Increasing evidence shows
that bupropion, a norepinephrine and dopamine reuptake inhibitor,
is one of the most widely chosen and effective augmenting
agents for depressive patients with insufficient response to serotonin
reuptake inhibitors. In this study, we evaluated the efficacy
and tolerability of bupropion augmentation in nonresponders to
escitalopram monotherapy in order to better understand this potential
approach to improving treatment outcome in depression.